Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV

Antiviral Therapy

Volumn 12, Issue SUPPL. 3, 2007, Pages

  Locarnini, Stephen ^a   Warner, Nadia ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CLEVUDINE; ENTECAVIR; LAMIVUDINE; MEMBRANE ANTIGEN; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE; TENOFOVIR; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

COMBINATION CHEMOTHERAPY; DISEASE COURSE; DNA TRANSCRIPTION; DRUG TARGETING; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIXED INFECTION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION; REVIEW; RISK ASSESSMENT; TREATMENT FAILURE; VIRUS GENOME; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENES, VIRAL; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; MUTATION;

EID: 38049091002     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Lok A. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992; 10:46-52.
2. Hadziyannis S. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1:7-36.
3. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4:936-962.
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
5. The EASL Jury. EASE International Consensus Conference on Hepatitis B. September 13-14, Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38:533-540.
6. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25:472-489.
7. Ganem D & Schneider R. Hepadnaviridae: the viruses and their replication. In Fields Virology. Edited by DM Knipe & PM Howley. Philadelphia, PA: Lippincott-Raven 2001; pp. 2923-2970.
8. Summers J, O'Connell A, Millman L. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci U S A 1975; 72:4597-4601.
9. Girones R, Miller RH. Mutation rate of the hepadnavirus genome. Virology 1989; 170:595-597.
10. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol 2004; 78:12725-12734.
11. Zoulim F, Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 1994; 68:6-13.
12. Seeger C & Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64:51-68.
13. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47:451-460.
14. Chisari F, Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 1995; 13:29-60.
15. Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003; 38:4-13.
16. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306-1310.
17. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921-1926.
18. Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: Lessons learned from treating HIV infected patients. J Hepatol 1999; 30:536-550.
19. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9:679-693.
20. Shaw T, Locarnini SA. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus. J Viral Hepat 1999; 6:89-106.
21. Liaw YF, Sung JJ, Chow WC, et al. Group Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
22. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120:1009-1022.
23. Nowak, MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:4398-4402.
24. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000; 32:866-867.
25. Zhang YY, Summers J. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. J Virol 1999; 73:3616-3622.
26. Zhang YY, Summers J. Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 2000; 74:5257-5265.
27. Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9:149-160.
28. Newbold JE, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995; 69:3350-3357.
29. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44:422-431.
30. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44:593-606.
31. Hong SP, Kim NK, Hwang SG, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004; 40:837-844.
32. Kim HS, Han KH, Ahn SH, et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther 2005; 10:441-449.
33. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687-696.
34. Delaney WE IV, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77:11833-11841.
35. Niesters HG, De Man RA, Pas SD, Fries E, Osterhaus AD. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002; 51:695-699.
36. Doo E, Liang JT. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001; 120:1000-1008.
37. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-1306.
38. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172-180.
39. Matthews GV, Bartholomeusz A, Locarnini S, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20:863-870.
40. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T, Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 1999; 59:270-276.
41. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrobl Agents Chemother 2004; 48:3498-3507.
42. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31:1318-1326.
43. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002; 293:305-313.
44. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with development of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297.
45. Westland CE, Yang H, Delaney WE IV, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38:96-103.
46. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681.
47. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354:1807-1812.
48. Chang TT, Lai CL. Hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 355:322-323.
49. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727-734.
50. Delaney WE IV, Ray AS, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50:2471-2477.
51. van Bommel F. Is tenofovir effective in treatment of adefovir resistant hepatitis B virus (HBV) infections? Hepatology 2006; 44 Suppl 1:567A.
52. Chang TT, Gish RG, De Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
53. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020.
54. Sherman M, Yurdayin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130:2039-2049.
55. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44:1656-1665.
56. McMahon M. The anti-hepatitis B drug entecavir inhibits HIV-1 replication and selects HIV-1 variants resistant to antiretroviral drugs. N Engl J Med 2007; 356:2614-2621.
57. Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43:937-943.
58. Mutimer D, Pillay D, Cook P, et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 2000; 181:713-716.
59. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41:1391-1398.
60. Villet S. Sequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virus. Hepatology 2005; 42 Suppl 1:581A.
61. Shafer RW, Winters MA, Palmer S, Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998; 128:906-911.
62. Gonzales MJ, Johnson E, Dupnik KM, Imamichi T, Shafer RW. Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing. J Acquir Immune Defic Syndr 2003; 34:398-402.
63. Natsuizaka M, Hige S, Ono Y, et al. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region. J Viral Hepat 2005; 12:154-159.
64. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107:449-455.
65. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44:703-712.
66. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the path forward? Drugs 2000; 60:517-531.
67. Sung JJ. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003; 38 Suppl 2:25-26.
68. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997; 4 Suppl 1:11-20.
69. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16:131-133.
70. Besisik F, Karaca C, Akyuz F, et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003; 38:506-510.